# Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

> **NCT01239368** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Myeloma, Plasma-Cell
- Myeloma-Multiple
- Myelomatosis

## Interventions

- **PROCEDURE:** Adoptive Immunotherapy
- **BIOLOGICAL:** Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)
- **BIOLOGICAL:** Th1/Tc1 Rapa Cell Therapy

## Key facts

- **NCT ID:** NCT01239368
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11-10
- **Primary completion:** 2017-08-16
- **Final completion:** 2017-08-16
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Terminated due to insufficient accrual.
- **Last updated:** 2019-12-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01239368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01239368, "Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01239368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*